BioRestorative Therapies, Inc.BRTX

The headline from BioRestorative Therapies, Inc.’s latest 10-Q is hard to spin: the company lost $2.2 million in the first quarter of 2026 while generating just $23,170 in revenue. That ratio-roughly $95 in losses for every dollar of sales-is the kind of arithmetic that makes even the most patient cell-therapy believer pause. The filing itself is a masterclass in brevity, offering no explanation for the thin revenue or the gaping hole in the income statement, leaving outsiders to speculate whether the company is shipping a handful of vials to a single clinic or if the $23k is the accounting equivalent of a polite nod in a crowded room. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1505497/000121390026069973/xslF345X06/primary_doc.xml).

What BioRestorative does is clear enough: it is a regenerative medicine company with a pipeline split between a cell therapy for chronic lumbar disc disease (BRTX-100) and a line of exosome-based “BioCosmeceuticals” aimed at the beauty market. The company’s recent 8-K boasts of completing Phase 2 manufacturing for BRTX-100, a step that sounds more impressive than it is when you remember that Phase 2 is where most cell therapies go to languish while regulators, insurers, and patients decide if the therapy is worth the risk. The BioCosmeceuticals angle, meanwhile, promises to turn wrinkles into wealth via exosome-infused creams, a pitch that sits somewhere between science and skincare fantasy until the company can show a single retail shelf stocked with its products. (source: BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, https://ir.biorestorative.com/news-events/press-releases; Clinical Trials pipeline, https://biorestorative.com/pipeline/).

The filings also reveal that BioRestorative spent $1.9 million on research and development in the quarter while haemorrhaging $3.8 million in operating cash. The company’s balance sheet shows $3.1 million in cash against $3.7 million in liabilities, a gap that would look healthier if the revenue line were anything other than microscopic. The company’s equity now stands at $3.0 million, a figure that feels less like a cushion and more like a speed bump on the road to the next financing round. The weighted average diluted share count sits at 17.7 million shares, a number that has likely ticked higher since the last filing as the company continues to fund its operations through equity rather than revenue. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1505497/000121390026069973/xslF345X06/primary_doc.xml).

If you’re looking for a chart, the only legitimate source route is the company’s investor relations page, where the filings and press releases are posted without the theatrics of a trading platform. The story here isn’t a share-price chart; it’s the gap between the company’s regenerative ambitions and the $23k it managed to bill in a quarter. Until that gap narrows-or until the company can explain why it’s so wide-the file remains a study in patience, not profit. (source: BioRestorative Therapies Investor Relations, https://ir.biorestorative.com/financial-information/financial-results).